Literature DB >> 8527441

Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction.

S Fiore1, C N Serhan.   

Abstract

Lipoxin A4 (LXA4) interacts with high-affinity receptors in human neutrophils and differentiated HL-60 cells. Recently, we characterized a myeloid-derived cDNA that encodes a LXA4 high-affinity receptor (LXA4R) [Fiore, S., Maddox, J. F., Perez, H. D., and Serhan, C. N. (1994) J. Exp. Med. 180, 253-260] denoted earlier as a related N-formyl peptide receptor (RFP). To examine the selectivity of this receptor we tested its preference for specific binding of 3H-LXA4 versus 3H-N-formylmethionyl-leucyl-phenylalanine (3H-FMLP). When receptor-transfected Chinese hamster ovary cells were exposed to either 3H-LXA4 or 3H-FMLP, the receptor affinity for LXA4 exceeded by 1000-fold that of FMLP (6.1 nM vs 5 microM). Upon differentiation, HL-60 cells acquire high-affinity binding sites and respond to both LXA4 and FMLP. Northern blot analysis of differentiated HL-60 cells using an RFP probe showed a characteristic band at 2.1 kb. Differentiated HL-60 cells exposed to an RFP antisense oligonucleotide selectively lost 3H-LXA4 binding as well as LXA4-stimulated lipid remodeling that paralleled the loss of mRNA for LXA4R. In contrast, the specific mRNA for the FMLP receptor, 3H-FMLP specific binding, and FMLP-induced phospholipase D activity were still observed. Treatment of human neutrophils with antisera raised against a peptide in the LXA4R third extracellular domain also resulted in selective abrogation of 3H-LXA4 specific binding with polymorphonuclear leukocytes (PMN) without blocking 3H-FMLP binding. FMLP-stimulated CD11b upregulation as well as homotypic aggregation of PMN was inhibited by LXA4 (which at 10(-9) M gave approximately 1 log unit shift to the right in the FMLP dose-response curve). The addition of LXA4R antisera did not alter FMLP-induced responses in PMN but completely blocked LXA4 actions. These results indicate that altering the expression of the LXA4R protein by blockage of transcriptional mechanisms or hindrance of the LXA4R extracellular domains leads to loss of LXA4 specific binding and blockage of LXA4 signaling. Moreover, they indicate that in myeloid cells LXA4-LXA4R interactions are dissociable from those of FMLP and that LXA4 regulates CD11/18 on the PMN surface.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527441     DOI: 10.1021/bi00051a016

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  36 in total

Review 1.  Paradigm shift in the pharmacological management of periodontal diseases.

Authors:  Hatice Hasturk; Alpdogan Kantarci; Thomas E Van Dyke
Journal:  Front Oral Biol       Date:  2011-11-11

2.  Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin.

Authors:  R Scalia; J Gefen; N A Petasis; C N Serhan; A M Lefer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

Review 3.  Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins.

Authors:  Matthew Spite; Charles N Serhan
Journal:  Circ Res       Date:  2010-11-12       Impact factor: 17.367

4.  Lipoxin A4, a 5-lipoxygenase pathway metabolite, modulates immune response during acute respiratory tularemia.

Authors:  Anju Singh; Tabassum Rahman; Rose Bartiss; Alireza Arabshahi; Jeevan Prasain; Stephen Barnes; Florin Marcel Musteata; Timothy J Sellati
Journal:  J Leukoc Biol       Date:  2016-09-14       Impact factor: 4.962

5.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 6.  Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases.

Authors:  Nandini Krishnamoorthy; Raja-Elie E Abdulnour; Katherine H Walker; Braden D Engstrom; Bruce D Levy
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

7.  Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury.

Authors:  Caroline Bonnans; Koichi Fukunaga; Marilyn A Levy; Bruce D Levy
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

8.  A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor.

Authors:  Aram Elagoz; Duncan Henderson; Poda Suresh Babu; Sylvia Salter; Caroline Grahames; Lorna Bowers; Marie-Odile Roy; Patricia Laplante; Eric Grazzini; Sultan Ahmad; Paola M C Lembo
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

9.  The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8.

Authors:  Huamei Fu; Johan Bylund; Anna Karlsson; Sara Pellmé; Claes Dahlgren
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

10.  An angiogenic role for the human peptide antibiotic LL-37/hCAP-18.

Authors:  Rembert Koczulla; Georges von Degenfeld; Christian Kupatt; Florian Krötz; Stefan Zahler; Torsten Gloe; Katja Issbrücker; Pia Unterberger; Mohamed Zaiou; Corinna Lebherz; Alexander Karl; Philip Raake; Achim Pfosser; Peter Boekstegers; Ulrich Welsch; Pieter S Hiemstra; Claus Vogelmeier; Richard L Gallo; Matthias Clauss; Robert Bals
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.